262 related articles for article (PubMed ID: 26985890)
1. Carbapenems to Treat Multidrug and Extensively Drug-Resistant Tuberculosis: A Systematic Review.
Sotgiu G; D'Ambrosio L; Centis R; Tiberi S; Esposito S; Dore S; Spanevello A; Migliori GB
Int J Mol Sci; 2016 Mar; 17(3):373. PubMed ID: 26985890
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of Carbapenems for Treatment of Multi- and Extensively Drug-Resistant
van Rijn SP; Zuur MA; Anthony R; Wilffert B; van Altena R; Akkerman OW; de Lange WCM; van der Werf TS; Kosterink JGW; Alffenaar JC
Antimicrob Agents Chemother; 2019 Feb; 63(2):. PubMed ID: 30455232
[TBL] [Abstract][Full Text] [Related]
3. Combined Use of Delamanid and Bedaquiline to Treat Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis: A Systematic Review.
Migliori GB; Pontali E; Sotgiu G; Centis R; D'Ambrosio L; Tiberi S; Tadolini M; Esposito S
Int J Mol Sci; 2017 Feb; 18(2):. PubMed ID: 28178199
[TBL] [Abstract][Full Text] [Related]
4. Comparison of effectiveness and safety of imipenem/clavulanate- versus meropenem/clavulanate-containing regimens in the treatment of MDR- and XDR-TB.
Tiberi S; Sotgiu G; D'Ambrosio L; Centis R; Abdo Arbex M; Alarcon Arrascue E; Alffenaar JW; Caminero JA; Gaga M; Gualano G; Skrahina A; Solovic I; Sulis G; Tadolini M; Alarcon Guizado V; De Lorenzo S; Roby Arias AJ; Scardigli A; Akkerman OW; Aleksa A; Artsukevich J; Auchynka V; Bonini EH; Chong Marín FA; Collahuazo López L; de Vries G; Dore S; Kunst H; Matteelli A; Moschos C; Palmieri F; Papavasileiou A; Payen MC; Piana A; Spanevello A; Vargas Vasquez D; Viggiani P; White V; Zumla A; Migliori GB
Eur Respir J; 2016 Jun; 47(6):1758-66. PubMed ID: 27076583
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness and safety of meropenem/clavulanate-containing regimens in the treatment of MDR- and XDR-TB.
Tiberi S; Payen MC; Sotgiu G; D'Ambrosio L; Alarcon Guizado V; Alffenaar JW; Abdo Arbex M; Caminero JA; Centis R; De Lorenzo S; Gaga M; Gualano G; Roby Arias AJ; Scardigli A; Skrahina A; Solovic I; Sulis G; Tadolini M; Akkerman OW; Alarcon Arrascue E; Aleska A; Avchinko V; Bonini EH; Chong Marín FA; Collahuazo López L; de Vries G; Dore S; Kunst H; Matteelli A; Moschos C; Palmieri F; Papavasileiou A; Spanevello A; Vargas Vasquez D; Viggiani P; White V; Zumla A; Migliori GB
Eur Respir J; 2016 Apr; 47(4):1235-43. PubMed ID: 26965290
[TBL] [Abstract][Full Text] [Related]
6. Comparative review of the carbapenems.
Zhanel GG; Wiebe R; Dilay L; Thomson K; Rubinstein E; Hoban DJ; Noreddin AM; Karlowsky JA
Drugs; 2007; 67(7):1027-52. PubMed ID: 17488146
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of ertapenem in patients with multidrug-resistant tuberculosis.
van Rijn SP; van Altena R; Akkerman OW; van Soolingen D; van der Laan T; de Lange WC; Kosterink JG; van der Werf TS; Alffenaar JW
Eur Respir J; 2016 Apr; 47(4):1229-34. PubMed ID: 26743484
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of meropenem-clavulanate added to linezolid-containing regimens in the treatment of MDR-/XDR-TB.
De Lorenzo S; Alffenaar JW; Sotgiu G; Centis R; D'Ambrosio L; Tiberi S; Bolhuis MS; van Altena R; Viggiani P; Piana A; Spanevello A; Migliori GB
Eur Respir J; 2013 Jun; 41(6):1386-92. PubMed ID: 22997218
[TBL] [Abstract][Full Text] [Related]
9. Ambulatory management of pre- and extensively drug resistant tuberculosis patients with imipenem delivered through port-a-cath: A mixed methods study on treatment outcomes and challenges.
Chavan VV; Dalal A; Nagaraja S; Thekkur P; Mansoor H; Meneguim A; Paryani R; Singh P; Kalon S; Das M; Ferlazzo G; Isaakidis P
PLoS One; 2020; 15(6):e0234651. PubMed ID: 32544174
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness and safety of bedaquiline-containing regimens in the treatment of MDR- and XDR-TB: a multicentre study.
Borisov SE; Dheda K; Enwerem M; Romero Leyet R; D'Ambrosio L; Centis R; Sotgiu G; Tiberi S; Alffenaar JW; Maryandyshev A; Belilovski E; Ganatra S; Skrahina A; Akkerman O; Aleksa A; Amale R; Artsukevich J; Bruchfeld J; Caminero JA; Carpena Martinez I; Codecasa L; Dalcolmo M; Denholm J; Douglas P; Duarte R; Esmail A; Fadul M; Filippov A; Davies Forsman L; Gaga M; Garcia-Fuertes JA; García-García JM; Gualano G; Jonsson J; Kunst H; Lau JS; Lazaro Mastrapa B; Teran Troya JL; Manga S; Manika K; González Montaner P; Mullerpattan J; Oelofse S; Ortelli M; Palmero DJ; Palmieri F; Papalia A; Papavasileiou A; Payen MC; Pontali E; Robalo Cordeiro C; Saderi L; Sadutshang TD; Sanukevich T; Solodovnikova V; Spanevello A; Topgyal S; Toscanini F; Tramontana AR; Udwadia ZF; Viggiani P; White V; Zumla A; Migliori GB
Eur Respir J; 2017 May; 49(5):. PubMed ID: 28529205
[TBL] [Abstract][Full Text] [Related]
11. Feasibility of a "Salvage Regimen" Using Home-based Intravenous Meropenem Therapy With a Delamanid/Bedaquilline Containing Regimen in the Management of MDR/XDR Pediatric Tuberculosis.
Shah I; Antony S; Jaiswal A; Bodhanwala M; Shah D; Tipre P; Salve J; Parmar M; Sachdeva KS
Pediatr Infect Dis J; 2022 May; 41(5):401-404. PubMed ID: 35153288
[TBL] [Abstract][Full Text] [Related]
12. Sulopenem: An Intravenous and Oral Penem for the Treatment of Urinary Tract Infections Due to Multidrug-Resistant Bacteria.
Zhanel GG; Pozdirca M; Golden AR; Lawrence CK; Zelenitsky S; Berry L; Schweizer F; Bay D; Adam H; Zhanel MA; Lagacé-Wiens P; Walkty A; Irfan N; Naber K; Lynch JP; Karlowsky JA
Drugs; 2022 Apr; 82(5):533-557. PubMed ID: 35294769
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness and safety of bedaquiline-containing regimens for treatment on patients with refractory RR/MDR/XDR-tuberculosis: a retrospective cohort study in East China.
Zhang SJ; Yang Y; Sun WW; Zhang ZS; Xiao HP; Li YP; Zhang ZM; Fan L
BMC Infect Dis; 2022 Aug; 22(1):715. PubMed ID: 36038829
[TBL] [Abstract][Full Text] [Related]
14. Towards tailored regimens in the treatment of drug-resistant tuberculosis: a retrospective study in two Italian reference Centres.
Riccardi N; Alagna R; Saderi L; Ferrarese M; Castellotti P; Mazzola E; De Lorenzo S; Viggiani P; Udwadia Z; Besozzi G; Cirillo D; Sotgiu G; Codecasa L;
BMC Infect Dis; 2019 Jun; 19(1):564. PubMed ID: 31253115
[TBL] [Abstract][Full Text] [Related]
15. Treatment outcomes of patients with multidrug-resistant and extensively drug resistant tuberculosis in Hunan Province, China.
Alene KA; Yi H; Viney K; McBryde ES; Yang K; Bai L; Gray DJ; Clements ACA; Xu Z
BMC Infect Dis; 2017 Aug; 17(1):573. PubMed ID: 28814276
[TBL] [Abstract][Full Text] [Related]
16. The risk of seizures among the carbapenems: a meta-analysis.
Cannon JP; Lee TA; Clark NM; Setlak P; Grim SA
J Antimicrob Chemother; 2014 Aug; 69(8):2043-55. PubMed ID: 24744302
[TBL] [Abstract][Full Text] [Related]
17. First series of patients with XDR and pre-XDR TB treated with regimens that included meropenen-clavulanate in Argentina.
Palmero D; González Montaner P; Cufré M; García A; Vescovo M; Poggi S
Arch Bronconeumol; 2015 Oct; 51(10):e49-52. PubMed ID: 26026689
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of World Health Organization group 5 drugs for multidrug-resistant tuberculosis treatment.
Winters N; Butler-Laporte G; Menzies D
Eur Respir J; 2015 Nov; 46(5):1461-70. PubMed ID: 26381514
[TBL] [Abstract][Full Text] [Related]
19. Bedaquiline safety, efficacy, utilization and emergence of resistance following treatment of multidrug-resistant tuberculosis patients in South Africa: a retrospective cohort analysis.
Pai H; Ndjeka N; Mbuagbaw L; Kaniga K; Birmingham E; Mao G; Alquier L; Davis K; Bodard A; Williams A; Van Tongel M; Thoret-Bauchet F; Omar SV; Bakare N
BMC Infect Dis; 2022 Nov; 22(1):870. PubMed ID: 36414938
[TBL] [Abstract][Full Text] [Related]
20. Use of Carbapenems against clinical, nontyphoid Salmonella isolates: results from in vitro and in vivo animal studies.
Tang HJ; Chen CC; Zhang CC; Cheng KC; Chiang SR; Chiu YH; Ku YH; Ko WC; Chuang YC
Antimicrob Agents Chemother; 2012 Jun; 56(6):2916-22. PubMed ID: 22470122
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
